Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Details)

v3.23.1
NON CONTROLLING INTEREST (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Net loss attributable to the non-controlling interest $ (934) $ (551)
BioCorRx Pharmaceuticals, Inc [Member]    
Net loss $ (1,447) $ (2,276)
Average Non-controlling interest percentage of profit/losses 24.20% 24.20%
Net loss attributable to the non-controlling interest $ (350) $ 551
Joseph DeSanto MD [Member]    
Net loss $ (1,668)  
Average Non-controlling interest percentage of profit/losses 35.00%  
Net loss attributable to the non-controlling interest $ (584)